Use of Levetiracetam in the Treatment of Epileptic Seizures

3054 Words7 Pages

Introduction Epilepsy is a serious global problem that affects approximately 1% of people worldwide (1). Epilepsy is a chronic condition of the central nervous system (CNS) characterized by epileptic seizures, which can affect physical and mental functions (2). Epileptic seizures are unprovoked reoccurring episodes of abnormal, excessive, or hypersynchronis neuronal activity in the CNS (2). The treatment options of epilepsy include medications called antiepileptic drugs (AED) and surgeries based on individuals’ specific diagnosis and background (1). The AED Keppra®, S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide, or Levetiracetam (LEV) is Food and Drug Administration (FDA)-approved for the treatment and prevention of epileptic seizures (3). However, the exact mechanism of action of Levetiracetam (LEV) is not currently understood and the anticonvulsant characteristics of LEV are different than other antiepileptic drugs (AEDs) (2). For instance, LEV does not present the ability to inhibit sodium channels or enhance g-aminobutyric acid (GABA) function like several other AEDs (1). The understanding of the mechanism of action of LEV as an AED is important to understand the cellular mechanisms and pathogenesis of epilepsy and develop new methods of treating epilepsy. Past studies have shown LEV to target high-voltage-activated (HVA) N-type calcium (Ca2+) channels, the synaptic vesicle protein 2A (SV2A), and inhibit inositol 1,4,5-triphosphate receptors (IP3R) and ryanodine receptors (RyR) activated calcium-induced calcium release (CICR) (1)(3)(4). Voltage-gated calcium (Ca2+) channels are cellular membrane proteins that are important for electrical and chemical signaling in cells (5). In neurons voltage-gated Ca2+ chan... ... middle of paper ... ...Calcium Channels. Cold Spring Harbor Perspectives in Biology, 3(8). doi: 10.1101/ 6. Nowack, A., Yao, J., Custer, K. L., Bajjalieh, S. M. (2010). SV2 Regulates Neurotransmitter Release Via Multiple Mechanisms. American Journal of Physiology Cell Physiology 299(5). doi:10.1152/ajpcell.00259.2010 7. Lee, C.-Y., Chen, C.-C., & Liou, H.-H. (2009). Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. British Journal of Pharmacology, 158(7), 1753-1762. doi: 10.1111/j.1476-5381.2009.00463.x 8. Gillard, M., Chatelain, P., & Fuks, B. (2006). Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. European Journal of Pharmacology, 536(1–2), 102-108. doi: http://dx.doi.org/10.1016/j.ejphar.2006.02.022

More about Use of Levetiracetam in the Treatment of Epileptic Seizures

Open Document